Clinical trials
SMA clinical trials
Below are recruiting sma clinical trials, each written for real people, not researchers. We’re tracking 49 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07578454Recruiting
Virtual reality rehabilitation for spinal muscular atrophy
This study tests a virtual reality rehabilitation program for young people with SMA (spinal muscular atrophy, a genetic muscle-weakening condition). Researchers want to understand if VR-based exercises can help improve function and quality of life.
OxfordAges 6–18 - NCT04292574Recruiting
UK Spinal Muscular Atrophy patient registry
This trial is a registry that collects health information from people with spinal muscular atrophy (SMA). It helps researchers understand the condition better and may support future studies and treatments.
Newcastle upon TyneAges Any age - NCT05331937RecruitingPhase 3
TMS plus exposure therapy for severe OCD that won’t improve
This trial studies whether TMS (a brain stimulation treatment) can help people with severe OCD who have not responded well to exposure therapy. It combines brain stimulation with intensive exposure therapy to reduce obsessions and compulsions.
Amsterdam, North HollandAges 18 years+ - NCT06322654Recruiting
Comparing two types of robotic rehab for spinal muscular atrophy
This study compares two robot-assisted rehabilitation programs to see which one helps children and young adults with spinal muscular atrophy (SMA) improve their movement and function better. You may join if you have SMA (types 1-4), are up to 21 years old, and are already receiving medication for SMA.
PoznanAges Up to 21 years - NCT03217578Recruiting
Newborn screening for spinal muscular atrophy in Taiwan
This trial offers testing for spinal muscular atrophy (SMA) to newborns. It aims to identify SMA early so families and doctors can act sooner if results suggest the condition.
Kaohsiung CityAges birth–2 weeks - NCT04174157Recruiting
Spinal muscular atrophy patient registry for OAV-101
This is a registry that collects information from people with spinal muscular atrophy (SMA) who have been treated with OAV-101. It helps researchers understand how patients do over time after this treatment.
Phoenix, ArizonaAges Any age - NCT05375968RecruitingPhase 2
Test blood-flow changes in POTS after meals
This Phase 2 study looks at how blood pools in the belly veins when you stand or eat, in people with POTS (postural tachycardia syndrome). The goal is to understand what’s driving symptoms like feeling nearly faint and whether this helps guide better care.
Nashville, TennesseeAges 18–50 - NCT06971094RecruitingPhase 3
Gene therapy for type 2 spinal muscular atrophy
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
BeijingAges 2–12 - NCT06978985Recruiting
Adult SMA research and clinical hub study
This study creates a registry and clinical hub for adults with 5q spinal muscular atrophy (SMA). It aims to track health outcomes and improve care for people living with SMA.
BirminghamAges 16 years+ - NCT07223489Recruiting
Understanding Adult SMA Diagnosis & Treatment Experiences
This trial explores the experiences of adults with spinal muscular atrophy (SMA) in the MedStar Health System, looking at how they are diagnosed and treated, and any differences in care they may face.
Washinton, District of ColumbiaAges 18 years+ - NCT07265232RecruitingPhase 3
Gene therapy for spinal muscular atrophy in low-resource settings
This trial tests a new gene therapy called Vesemnogene Lantuparvovec for people with spinal muscular atrophy (SMA). It is designed for patients in low- and middle-income countries who cannot access or did not respond to other treatments. The goal is to see if the therapy is safe and effective in real-world conditions.
Jakarta, IndonesiaAges 6 months+ - NCT07420777Recruiting
3D-printed aligners for treating an open bite
This study tests whether new 3D-printed shape-memory aligners can effectively fix a mild-to-moderate open bite (when front teeth don't touch when you bite down). It may be a good option if you are between 18 and 35, generally healthy, and have a mild open bite with fairly straight teeth.
Erbil, Erbil GovernorateAges 18–35 - NCT07444476RecruitingPhase 3
Study of salanersen for spinal muscular atrophy (ages 15-60)
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
Norfolk, VirginiaAges 15–60 - NCT07488338Recruiting
Movement and hand training for children with SMA
This study tests whether a combined program of home-based activities and hand training can help children with spinal muscular atrophy improve their movement and daily function. It is for children who can sit or walk with support and have been on stable medication for at least 6 months.
New York, New YorkAges 5–17 - NCT07287982RecruitingPhase 2
ARGX-119 for children with SMA who can walk
This study tests a new medicine called ARGX-119 in children with SMA. It is given through an IV and aims to help kids who can already walk get stronger and stay healthy.
Little Rock, ArkansasAges 5–17 - NCT07221669RecruitingPhase 3
Pre-symptomatic salanersen study for babies with SMA
This trial tests if the drug salanersen can help movement and is safe when given to babies diagnosed with spinal muscular atrophy before they show symptoms. It's for very young infants with specific genetic types of SMA.
Chicago, IllinoisAges birth–1 month - NCT07444450RecruitingPhase 3
Study of salanersen for babies with SMA previously treated with gene therapy
This study tests a new medicine called salanersen in babies who have already received gene therapy for SMA. It aims to see if adding salanersen is safe and effective.
Flower Mound, TexasAges birth–7 months - NCT05558566Recruiting
Neurofeedback training for Tourette-related tics in teens
This study tests whether brain training using “neurofeedback” can reduce Tourette syndrome tics in children ages 10–16. It compares an active neurofeedback condition to a control condition while measuring brain activity with an MRI.
New Haven, ConnecticutAges 10–16 - NCT05102916Recruiting
Registry for neuromuscular disorder patients in Switzerland
This study is a patient registry that collects health information from people diagnosed with a neuromuscular disorder in Switzerland. It helps researchers better understand these conditions and how they vary from person to person.
Aarau, Canton of AargauAges birth+ - NCT07001943Recruiting
Blood flow in stomach and gut injury in ICU patients
This trial checks if changes in blood flow to the stomach and intestines can predict gut injury in critically ill patients who need feeding through a tube. It uses a safe ultrasound test at the bedside.
Beijing, Beijing MunicipalityAges 18–80 - NCT05954455Recruiting
Studying speech and swallowing development in children with SMA type 1
This study looks at how speech, communication, and swallowing (“bulbar function”) develop in babies and children with SMA type 1. It aims to better understand what to expect over time for children who start approved SMA treatments early.
LondonAges birth–18 years - NCT07531719Recruiting
Risdiplam treatment study for type I and II spinal muscle atrophy
This study follows children with spinal muscular atrophy (SMA)—a genetic condition causing muscle weakness—who are being treated with a medicine called risdiplam. Researchers want to understand how well the treatment works and how it affects daily life in young patients.
CairoAges Up to 5 years - NCT04010604Recruiting
Study of spinal muscular atrophy in patients and carriers
This is a long-term observation study that follows people affected by spinal muscular atrophy (SMA), people who carry the SMA gene but have no symptoms, and families of people with SMA. It helps researchers better understand SMA and related genetic status, which can support future treatment planning.
Fuzhou, FujianAges 1 week–70 years - NCT05747261RecruitingPhase 1/Phase 2
Single-dose gene therapy for children with spinal muscular atrophy
This trial tests a one-time gene therapy given through a vein to add a working SMN gene in children with spinal muscular atrophy (SMA). It mainly looks at safety first, and also checks early signs that treatment helps the disease.
MinskAges Up to 8 months
Hear when a new SMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sma?
- Yes. Clin2 currently lists 49 recruiting sma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.